Invited Commentary: Treatment Drop-in-Making the Case for Causal Prediction.

counterfactual causal inference risk prediction treatment drop-in

Journal

American journal of epidemiology
ISSN: 1476-6256
Titre abrégé: Am J Epidemiol
Pays: United States
ID NLM: 7910653

Informations de publication

Date de publication:
01 10 2021
Historique:
received: 25 01 2021
revised: 25 01 2021
accepted: 02 02 2021
pubmed: 18 2 2021
medline: 15 10 2021
entrez: 17 2 2021
Statut: ppublish

Résumé

Clinical prediction models (CPMs) are often used to guide treatment initiation, with individuals at high risk offered treatment. This implicitly assumes that the probability quoted from a CPM represents the risk to an individual of an adverse outcome in absence of treatment. However, for a CPM to correctly target this estimand requires careful causal thinking. One problem that needs to be overcome is treatment drop-in: where individuals in the development data commence treatment after the time of prediction but before the outcome occurs. In this issue of the Journal, Xu et al. (Am J Epidemiol. 2021;190(10):2000-2014) use causal estimates from external data sources, such as clinical trials, to adjust CPMs for treatment drop-in. This represents a pragmatic and promising approach to address this issue, and it illustrates the value of utilizing causal inference in prediction. Building causality into the prediction pipeline can also bring other benefits. These include the ability to make and compare hypothetical predictions under different interventions, to make CPMs more explainable and transparent, and to improve model generalizability. Enriching CPMs with causal inference therefore has the potential to add considerable value to the role of prediction in healthcare.

Identifiants

pubmed: 33595073
pii: 6140870
doi: 10.1093/aje/kwab030
pmc: PMC8485150
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

2015-2018

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 218554/Z/19/Z
Pays : United Kingdom

Commentaires et corrections

Type : CommentOn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.

Références

Nature. 2020 Feb;578(7793):34-36
pubmed: 32020122
PLoS One. 2010 Jan 08;5(1):e8580
pubmed: 20072614
BJOG. 2016 Jun;123(7):1060-4
pubmed: 26806638
BMJ. 2017 May 23;357:j2099
pubmed: 28536104
CMAJ. 2013 Jul 9;185(10):E499-505
pubmed: 23339155
Diagn Progn Res. 2018 Dec 18;2:23
pubmed: 31093570
Stat Med. 2018 Dec 10;37(28):4142-4154
pubmed: 30073700
J Clin Epidemiol. 2016 Oct;78:90-100
pubmed: 27045189
BMC Med Res Methodol. 2017 Jul 14;17(1):103
pubmed: 28709404
Am J Epidemiol. 2013 Feb 15;177(4):292-8
pubmed: 23371353
J Am Med Inform Assoc. 2019 Dec 1;26(12):1675-1676
pubmed: 31722385
Diagn Progn Res. 2021 Feb 4;5(1):3
pubmed: 33536082
Biostatistics. 2020 Apr 1;21(2):345-352
pubmed: 31742354
Am J Epidemiol. 2017 Oct 15;186(8):1010-1014
pubmed: 28535275
Heart. 2011 May;97(9):689-97
pubmed: 21474616
Eur J Epidemiol. 2020 Jul;35(7):615-617
pubmed: 32623620
Stat Med. 2019 Feb 28;38(5):792-808
pubmed: 30328123
Eur J Epidemiol. 2020 Jul;35(7):619-630
pubmed: 32445007
Ann Intern Med. 2015 Jan 6;162(1):55-63
pubmed: 25560714
Stat Med. 2021 Feb 28;40(5):1101-1120
pubmed: 33241607

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH